37RI image
Deposition Date 2026-08-01
Release Date 2026-11-04
Last Version Date 2026-11-04
Entry Detail
PDB ID:
37RI
Title:
Multi-parameter optimization of a novel anti-TROP2 MMAE Antibody-Drug-Conjugate for solid tumor therapy
Biological Source:
Source Organism(s):
Homo sapiens (Taxon ID: 9606)
Method Details:
Experimental Method:
Resolution:
2.30 Å
R-Value Free:
0.26
R-Value Work:
0.22
R-Value Observed:
0.22
Space Group:
P 1 21 1
Macromolecular Entities
Structural Superimposition Protein Blast
Polymer Type:polypeptide(L)
Molecule:MK6837 Heavy Chain
Chain IDs:A, C
Chain Length:241
Number of Molecules:2
Biological Source:Homo sapiens
Structural Superimposition Protein Blast
Polymer Type:polypeptide(L)
Molecule:MK6837 Light Chain
Chain IDs:B, D
Chain Length:234
Number of Molecules:2
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Molecule:Tumor-associated calcium sign
Gene (Uniprot):TACSTD2
Chain IDs:E, F
Chain Length:284
Number of Molecules:2
Biological Source:Homo sapiens
Primary Citation

Abstact

TROP2 is expressed in many epithelial tumors including breast and lung cancers. It is a clinically validated ADC target based on approvals of sacituzumab govitecan for triple-negative breast cancer and datopotamab deruxtecan for HR-positive, HER2-negative breast cancer. An alternative cytotoxic approach was previously tested with PF-06664178/RN927C, an anti-TROP2 ADC with an auristatin payload, which entered clinical studies but could not be dosed efficaciously due to dose-limiting toxicities including skin rash, mucosal inflammation, and neutropenia. TroptimAb-SL-MMAE was engineered using an optimized anti-TROP2 sacituzumab antibody sequence (TroptimAb) to address issues related to hydrophobicity, non-specific uptake, and ADC developability. Sacituzumab was re(-)humanized and modified to enhance FcRn-mediated salvage which extended systemic half-life and potentially improving tumor distribution. Its affinity was avidity-tuned to preferentially bind cells with higher TROP2 expression to reduce on-target/off-tumor toxicity. An engineered cysteine in the Fc domain enabled generation of a homogeneous DAR2 ADC and shielded the linker-payload to reduce hydrophobicity and improve biophysical properties. Linker conjugation chemistry was also optimized to improve stability versus earlier cysteine-conjugated ADCs. We describe the preclinical profile of TroptimAb-SL-MMAE including its design, mechanism of action, anti-tumor activity, and pharmacokinetics.

Legend

Protein

Chemical

Disease

Primary Citation of related structures
Feedback Form
Name
Email
Institute
Feedback